Kiora Pharmaceuticals — Third Quarter 2026 Earnings Summary

Kiora Pharmaceuticals reported a net loss of $1.7 million for the third quarter of 2026, ending the period with approximately $16.3 million in cash and short-term investments. The company in-licensed exclusive development rights outside Asia for KIO-401, a late-stage oral calpain inhibitor, and has submitted a Type B pre-IND meeting request and an orphan drug designation request to the FDA for its use in treating Central Retinal Artery Occlusion. KIO-301 remains in Phase 2 development with the ABACUS-2 trial actively enrolling patients, while the company also expanded its commercial network by out-licensing rights in South Korea to Chong Kun Dang Pharmaceutical Corporation. Additionally, Kiora discontinued further research and development investment in KIO-104 and appointed Keith Lane as Executive Vice President of Clinical Development and Regulatory Affairs.